Decadron Ocumeter Side Effects
Generic name: dexamethasone ophthalmic
Medically reviewed by Drugs.com. Last updated on Jul 15, 2021.
Note: This document contains side effect information about dexamethasone ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Decadron Ocumeter.
For the Consumer
Applies to dexamethasone ophthalmic: intraocular implant, intraocular suspension
Other dosage forms:
Side effects requiring immediate medical attention
Along with its needed effects, dexamethasone ophthalmic (the active ingredient contained in Decadron Ocumeter) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking dexamethasone ophthalmic:
- Bloody eye
- blurred vision
- change in vision
- eye pain
- loss of vision
- redness of the white part of the eye or inside of the eyelid
- sensitivity of the eye to light
- swelling of the eye
- throbbing pain
- decreased vision
- gradual loss of vision
- itching of the eyelid
- seeing a veil or curtain across part of your vision
- seeing flashes or sparks of light
- seeing floating spots before the eyes
Side effects not requiring immediate medical attention
Some side effects of dexamethasone ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Difficulty seeing at night
- dry eye
- feeling of having something in the eye
For Healthcare Professionals
Applies to dexamethasone ophthalmic: intraocular implant, intraocular suspension, ophthalmic insert, ophthalmic ointment, ophthalmic solution, ophthalmic suspension
Very common (10% or more): Cataract (up to 68%), elevation of intraocular pressure (28%), conjunctival hemorrhage (22%)
Common (1% to 10%): Eye pain, conjunctival hyperemia, ocular hypertension, reduced visual acuity, conjunctivitis, vitreous floaters, conjunctival edema, dry eye, vitreous detachment, vitreous opacities, retinal aneurysm, foreign body sensation, corneal erosion, keratitis, anterior chamber inflammation, retinal tear, eyelid ptosis, vitreous detachment, keratoconjunctivitis sicca, corneal staining, photophobia, blurred vision, eye pruritus, increased lacrimation
Rare (less than 0.1%): Burning, stinging
Frequency not reported: Glaucoma with optic nerve damage, visual acuity and visual field defects, subcapsular cataract formation, secondary ocular infection and perforation of the globe
Postmarketing experience: Complication of device insertion (implant misplacement), device dislocation with or without corneal edema, endophthalmitis, hypotony of the eye (associated with vitreous leakage due to injection), retinal detachment[Ref]
Very common (10% or more): Hypertension (13%)[Ref]
Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Dysgeusia, migraine
Frequency not reported: Dizziness[Ref]
Common (1% to 10%): Bronchitis[Ref]
Cushing's syndrome and adrenal suppression may occur at doses higher than recommended in predisposed patients including children and those on CYP P450 3A4 inhibitors.
Postmarketing reports: Cushing's syndrome, adrenal suppression
More about Decadron Ocumeter (dexamethasone ophthalmic)
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Drug class: ophthalmic steroids
Related treatment guides
1. Cerner Multum, Inc. "Australian Product Information." O 0
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. "Product Information. Ozurdex (dexamethasone ophthalmic)." Allergan Inc, Irvine, CA.
4. "Product Information. Decadron Ocumeter (dexamethasone ophthalmic)." Merck & Co, Inc, West Point, PA.
Some side effects may not be reported. You may report them to the FDA.